You have free access to this content

Changes in the USP Heparin Monograph and Implications for Clinicians

  1. Dr. Maureen A. Smythe Pharm.D., FCCP1,2,*,
  2. Dr. Edith A. Nutescu Pharm.D., FCCP3,
  3. Dr. Ann K. Wittkowsky Pharm.D., FASHP, FCCP4

Article first published online: 6 JAN 2012

DOI: 10.1592/phco.30.5.428

Issue

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Volume 30, Issue 5, pages 428–431, May 2010

Additional Information

How to Cite

Smythe, M. A., Nutescu, E. A. and Wittkowsky, A. K. (2010), Changes in the USP Heparin Monograph and Implications for Clinicians. Pharmacotherapy, 30: 428–431. doi: 10.1592/phco.30.5.428

Author Information

  1. 1

    Department of Pharmaceutical Services, Beaumont Hospital, Royal Oak, Michigan

  2. 2

    Department of Pharmacy Practice, Wayne State University, Detroit, Michigan

  3. 3

    Department of Pharmacy Practice and Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois

  4. 4

    University of Washington School of Pharmacy, and Anticoagulation Services, University of Washington Medical Center, Seattle, Washington.

*Department of Pharmacy Services, Beaumont Hospital, Royal Oak, MI 48073; e-mail: msmythe@beaumont.edu.

Publication History

  1. Issue published online: 6 JAN 2012
  2. Article first published online: 6 JAN 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (52K)

References

  • 1
    Szajek A., Jameison F. USP heparin monograph revisions— stage 2 and beyond. Available from http:www.usp.orgpdfENmeetingsworkshopsheparin2009Szajek.pdf. Accessed January 29, 2010.
  • 2
    Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008;359(25): 2674–84.
  • 3
    U.S. Pharmacopeia. USP heparin information. Available from www.usp.orghottopicsheparin. Accessed January 29, 2010.
  • 4
    U.S. Food and Drug Administration. FDA public health alert: change in heparin USP monograph. Available from http:www.fda.govDrugsDrugSafetyPostmarketDrugSafetyInformationforPatientsandProvidersucm184502.htm. Accessed January 29, 2010.
  • 5
    U.S. Food and Drug Administration. FDA alert: New USP standards for heparin products will result in decreased potency. Adjustments may be needed to achieve desired anticoagulant effect in some patients. New heparin to ship starting October 8. Available from http:www.fda.govNewsEventsNewsroomPressAnnouncementsucm184674.htm. Accessed January 29, 2010.
  • 6
    American College of Chest Physicians. FDA announces new standards for heparin. Available from www.chestnet.orgaccp articlefda-announces-new-standards-heparin. Accessed January 29, 2010.
  • 7
    Hirsh J., Bauer KA, Donati MB, Gould M., Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians evidence-based practice guidelines (8th edition). Chest 2008;133: 141S–59.
  • 8
    Nutescu E., Singh-Khalsa M., and the Heparin Consensus Group. Treatment of venous thromboembolism: challenging the unfractionated heparin standard. Pharmacotherapy 2004;24(8 pt 2): 127S–31.
    Direct Link:
  • 9
    Kearon C., Kahn SR, Agnelli G., Goldhaber S., Raskob GE, Comerota AJ. Antithrombotic therapy for venous thrombo-embolic disease: American College of Chest Physicians evidence-based practice guidelines (8th edition). Chest 2008; 133: 454S–545.
  • 10
    American College of Cardiology, American Heart Association. 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction). J Am Coll Cardiol 2007;50: 1–157.
  • 11
    Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA. Anticoagulation monitoring. Part 2: unfractionated heparin and low molecular-weight heparin. Ann Pharmacother 2005;39: 1275–85.
  • 12
    Smythe MA, Koerber JM, Westley SJ, et al. Use of the activated partial thromboplastin time for heparin monitoring. Am J Clin Pathol 2001;115: 148–55.
  • 13
    Smythe MA, Koerber JM, Nowak SN, et al. Correlation between the activated clotting times and activated partial thromboplastin times. Ann Pharmacother 2002;36(1): 7–11.
  • 14
    Francis JL, Groce JB III, and the Heparin Consensus Group. Challenges in variation and responsiveness of unfractionated heparin. Pharmacotherapy 2004;24(8 pt 2): 108S–19.
    Direct Link:
  • 15
    Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006;96: 547–52.
  • 16
    Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy, laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1988;122: 782–98.
  • 17
    Smythe MA, Koerber JM, Westley SJ, Balasubramaniam M., Mattson JC. Different heparin lots, does it matter Arch Pathol Lab Med 2001;125: 1458–62.
  • 18
    Kovacs MJ, Keeney M., Mackinnon K., et al. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999;21: 55–60.
    Direct Link:
  • 19
    Baker BA, Adelman MS, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Arch Intern Med 1997;147: 2475–9.
  • 20
    Kearon C., Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006;296: 935–42.
Get PDF (52K)